Skip to main content
. 2021 Feb 9;19(4):1018–1028. doi: 10.1111/jth.15241

Figure 2.

Figure 2

Antibody‐beta2‐glycoprotein I (β2GPI) but not antibody‐prothrombin complexes attenuate activated factor X (FXa)‐dependent factor V (FV) activation. A, B, FV was activated with FXa at either 4 (A) or 500 (B) µM phospholipids, with or without β2GPI and a monoclonal anti‐β2GPI antibody (3B7). C, FV was activated with FXa at either 4 or 500 µM phospholipids, with or without prothrombin active site mutant (FIIi) or a monoclonal anti‐prothrombin antibody (28F4). Data are expressed as relative FV activity compared to the conditions without antibodies (n = 3–5). Significant differences were determined between samples with and without β2GPI or FIIi using a Mann‐Whitney test. *P‐value<0.05, **P‐value<0.01